I. To evaluate if there is sufficient evidence to continue to the phase III component by evaluating the objective response rate (ORR) for PI3K Genentech (GNE)-positive patients registered to S1400B treated with GDC-0032. (Phase II) II. If the study meets the criteria specified in S1400, the study will be amended to include a follow-on randomized phase III trial.